Skip to main content

Table 2 Recurrence-free survival for the total cohort and by tumor subtype

From: Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy

Treatment group Overall (N = 721, P = 0.45) HR (n = 143, P = NA) HER2-amplified (n = 312, P = 0.42) TN (n = 216, P = 0.59)
No. of patients 5-yr RFS (%) No. of patients 5-yr RFS (%) No. of patients 5-yr RFS (%) No. of patients 5-yr RFS (%)
A no T 56 93 (86–100)  a  a 22 86 (73–100)
A + T 367 91 (88–94) 124 92 (87–97) 55 89 (80–98) 170 92 (87–96)
AT + HER2 227 93 (89–96)  a 220 93 (90–97)  a
PC 71 85 (78–94) 11 80 (58–100) 33 91 (81–100) 21 85 (72–100)
  1. Abbreviations: HR Hormone receptor, TN Triple-negative breast cancer, A no T Adriamycin-based therapy alone, A + T Adriamycin plus taxane, AT + HER2 HER2-targeted therapy, PC provider choice
  2. aMissing cells < 10 patients
\